Wednesday was a fourth consecutive positive day for the U.S. markets, again with a rocky start just like Tuesday. All three major exchanges showed some love on Valentines Day, each returning over…
The January 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The top analyst upgrades, downgrades and other research calls from Monday include Amgen, Boeing, Chevron, Exxon Mobil, Foot Locker, Lowe's, Nokia, PayPal, Sprint and Wells Fargo.
The top analyst upgrades, downgrades and other research calls from Wednesday include AK Steel, Apple, Biogen, Electronic Arts, FitBit, Foot Locker, McDonald's and Pfizer.
The January 12 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
The top analyst upgrades, downgrades and other research calls from Tuesday include Amazon.com, Boeing, Chesapeake Energy, Eli Lilly, Gilead Sciences, Micron Thecnology, NVIDIA, Procter & Gamble and Qualcomm.
The December 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Although Monday was a relatively mixed day for the markets, all three of the major exchanges hit all-time highs yet again. This is only the fifth trading day of the New Year…
There can be some big biotech winners in 2018, given the changing landscape, and any of these 12 could be one.
Jefferies has put together a list of 10 biotech companies that could have developments coming up in the next two weeks to start the year.
The December 15 short interest data have been compared with the previous report, and short interest in the selected biotech stocks increased.
The top analyst upgrades, downgrades and other research calls from Wednesday include Alcoa, Extreme Networks, Gilead Sciences, MGIC, Micron, Noble Energy, Twitter, U.S. Steel and Wendy's
The November 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
One industry that could be a huge winner from tax reform, and may surprise some investors, is biotechnology, especially for the large cap leaders in the group.
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
